Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL019 in Chinese adults with relapsed/refractory DLBCL
CTR20211417Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Started Jun 2021; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20211417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211417.